Our choice of metformin as a proof-of-concept test as a CI inhibitor 79 in these orthotopic models was based on several factors: (1) it could easily be taken forward safely into in vivo studies with known target concentrations
Water, butylene glycol (1,3, butanediol), tocofersolan, hyaluronic acid, ethanol, caprylyl glycol, medium chain triglycerides, copper tripeptide-1 (GHK-Cu), highly purified phospholipids, natural mixed tocopherols, Psoralea corylifolia seed/leaf extract (Bakuchiol), tetrahexyldecyl ascorbate, lavender essential oil, Curcumin C3 Reduct (turmeric rhizome extract) (standardized to 95% tetrahydrocurcuminoids), Astragalus membranaceus root extract (standardized to 98% cyclosastragenol)
Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
Any hospital that submits data to NHSN after the HAC Reduction Program data submission deadline has passed
4GI, S7C, and Supplementary Data S4)